Not finding it? Sign in to also search OpenAlex live.
-
Identification of a Disease-Associated Network of Intestinal Immune Cells in Treatment-Naive Inflammatory Bowel Disease2022 Frontiers in Immunology article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Vincent van Unen, Laura F. Ouboter, Na Li, Mette Schreurs, Tamim Abdelaal, Yvonne Kooy–Winkelaar, +13 more
33citations -
ESMO–ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors
Evert S.M. van Aken, Bharti Devnani, Arsela Prelaj, Luís Castelo-Branco, Corrie A.M. Marijnen, Diogo Alexandre Martins-Branco, +21 more
30citations -
Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study2020 Journal for ImmunoTherapy of Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access cited by 1 patent
Els M.E. Verdegaal, Monique K. van der Kooij, Marten Visser, Caroline E. van der Minne, Linda de Bruin, Pauline Meij, +8 more
29citations -
Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers
Saskia Lisa Verhaart, Yasmin Abu‐Ghanem, Sasja F. Mulder, Sjoukje F. Oosting, Astrid Aplonia Maria Van Der Veldt, Susanne Osanto, +15 more
25citations -
Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective
Geeske F. Grit, Esmée van Geffen, Ruben Malmberg, Roelof van Leeuwen, Stefan Böhringer, Hans J.M. Smit, +11 more
18citations -
LBA57 Two-year clinical update and first biomarker analyses of the phase III NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma2025 Annals of Oncology conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access
M.W. Lucas, Alexander Maxwell Menzies, Petros Dimitriadis, S C M A Wijnen, Marta López‐Yurda, Richard A. Scolyer, +13 more
15citations -
Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions2022 Journal for ImmunoTherapy of Cancer article Medicine Cervical Cancer and HPV Research Open access cited by 1 patent
Ziena Abdulrahman, Natasja Hendriks, Arnold‐Jan Kruse, Antonios Somarakis, Anna J. M. van de Sande, Heleen J. van Beekhuizen, +7 more
15citations -
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial
Robert John Motzer, Ray McDermott, Se Hoon Park, Mauricio Burotto, Roberto Iacovelli, Elena Verzoni, +87 more
11citations -
Pre-existing infiltration with T cells and CD14+ myeloid cells is associated with treatment response to imiquimod in primary and recurrent vulvar high-grade squamous intraepithelial lesions2025 Journal for ImmunoTherapy of Cancer article Medicine Cervical Cancer and HPV Research Open access
Caroline L. P. Muntinga, Peggy J. de Vos van Steenwijk, Loes F. S. Kooreman, Sigrid Regauer, Ziena Abdulrahman, Ruud L.M. Bekkers, +3 more
3citations -
POS0003 RITUXIMAB THERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS – TRANSIENT EFFECTS ON AGE ASSOCIATED B-CELLS2021 Annals of the Rheumatic Diseases conference-abstract Medicine Systemic Lupus Erythematosus Research
Francesca Faustini, Natalie Sippl, Ragnhild Stålesen, Karine Chemin, Iva Gunnarsson, Vivianne Malmström
3citations -
PD1+ T-cells correlate with Nerve Fiber Density as a prognostic biomarker in patients with resected perihilar cholangiocarcinoma2022 bioRxiv (Cold Spring Harbor Laboratory) preprint Medicine Cholangiocarcinoma and Gallbladder Cancer Studies Open access
Xiuxiang Tan, Mika Rosin, Simone Appinger, Jan Bednarsch, Dong Liu, Georg J. Wiltberger, +19 more
1citations